Abbreviations: ARA-C = cytosine arabinoside; ATG = antithymocyte globulins; Bu = busulfan; Clo = clofarabine; Cy = cyclophosphamide; Flu = fludarabine; Mel = melphalan.
Pneumocystis jirovecii pneumonia (PJP) contributes to significant mortality and morbidity in immunosuppressed patients. Patients who have undergone allogeneic hematopoietic progenitor cell (HPC) transplant are, therefore, highly susceptible to PJP. Further suppression of the immune systems occurs when corticosteroids and other secondary immunosuppressive agents are added to treat GVHD to those given for GVHD prophylaxis. It has been estimated that up to 16% of HPC transplant recipients develop PJP if chemoprophylaxis is not given to these patients. 1 The mortality rates have varied, with rates as high as 89%. 2 Pre-emptive PJP prophylaxis in this group of high-risk patients is appropriate.
The most commonly used prophylactic agent is the combination of trimethoprim/sulfamethoxamide (TMP-SMZ). Although it is effective, adverse reactions such as skin rash, nausea and vomiting are common. Furthermore, it potentially suppresses the regenerating bone marrow. Up to 47% of HIV patients required an alternative to TMP-SMZ because of side effects. 3 Dapsone is better tolerated but is associated with a high breakthrough infection rate of 7.2%. 4 Nebulized pentamidine provides an alternative, with a breakthrough infection rate of between 1.2 and 2.7%. 5, 6 However, the administration of nebulized pentamidine requires specialized equipment and personnel.
Since 2011, IV pentamidine has been administered as PJP prophylaxis to all patients undergoing allogeneic HPC transplant in our program. The standard regimen consisted of IV pentamidine, at a dose of 4 mg/kg every 4 weeks. The first dose of pentamidine given just before transplant, coincided with the administration of the conditioning regimen for the transplant. The pentamidine was continued for as long as the patients were on immunosuppressive agents or being treated for GVHD. In patients with an elevated serum creatinine, the dose of pentamidine was reduced to 2 mg/kg.
Here, we report the results of a retrospective cohort study of adult patients who received IV pentamidine for PJP prophylaxis following allogeneic HPC transplants from January 2011 to December 2013. The follow-up data for all the patients were collected through December 2014. IV pentamidine was given as primary PJP prophylaxis as none of these patients had a history of PJP before their transplant. Only patients who had received at least one dose of IV pentamidine were included for toxicity evaluation. Success was considered if the patient did not develop PJP, with at least 4 weeks of follow-up from receiving the pentamidine, and failure was considered if the patient developed PJP anytime in the period after receiving the pentamidine. For analyzing changes in the renal functions because of pentamidine infusions, the serum creatinine measurements made closest to the infusion dates, but up to 4 weeks before and after each of the infusions were used. Infusion-related side effects were obtained from the infusion records for each of the patients.
A total of 99 allogeneic HPC transplants (5 s transplants) involving 94 patients were included for analysis. Patients in 16 transplants had received IV pentamidine as primary prophylaxis with their pre-transplant therapy. The clinical characteristics of the patients are shown in Table 1 . Three-fifths of the patients were male and two-fifths female. The median age of the patients at transplant was 52 years (range 22-73 years). The majority of the transplants were carried out in patients with primary myeloid malignancies (AML and myelodysplastic syndrome; 64%). Sixty- four transplants were from unrelated donors (thirteen with one antigen mismatch) and thirty-five from related donors. The conditioning regimens for approximately half of the transplants were myeloablative and the other half were non-myeloablative or reduced intensity. The most common myeloablative conditioning regimen used for the transplant was high-dose busulfan and cyclophosphamide (35%). All patients were severely immunosuppressed. Five of the transplants were second transplants, all within 2 years of the first transplants. GVHD prophylaxis for the patients is shown in Table 1 . Cyclosporine A combined with a short course of low-dose IV methotrexate (50%) or with mycophenolate (30%) were the most common GVHD prophylaxis. Twenty-one patients also received either antithymocyte globulin (20) or Campath-1H (1), and one patient received high-dose cyclophosphamide post transplant. In patients who developed GVHD, additional immunosuppressive agents were also added, including corticosteroids, mycophenolate, etanercept or photopheresis.
A total of 883 doses of IV pentamidine were administered (Figure 1 ), 21 (2%) doses administered at 2 mg/kg due to impaired renal functions. The median number of doses was 8 (range 1-33). Nearly, 30% (26/99) patients received 12 or more doses of the IV pentamidine. IV pentamidine was continued as the PJP prophylaxis in all the patients who developed chronic GVHD. Sixteen transplants received only one or two doses of IV pentamidine because they died from either multi-organ failure or disease relapse early post transplant.
Clinical adverse reactions were evaluable for all 883 doses of IV pentamidine administered. Infusion-related side effects were not documented in any of the patients. In particular, we did not record any nausea, vomiting, tachyarrhythmias, hypotension or bronchospasm. The pre-and post-infusion serum creatinine levels were available for 862 doses. The median time of creatinine measurement before pentamidine was 0 days (range 0-28 days) and after pentamidine was 10 days (range 1-28 days). As a group, there was not any clinically significant change in the serum creatinine because of the infusion, with the mean serum creatinine at 1.05 mg/dL before and at 1.07 mg/dL after infusion. However, increases in the mean serum creatinine from 1.3 mg/dL before to 1.7 mg/dL were observed following 18 (2%) infusions of the IV pentamidine (P o0.0001). We did not observe any case of PJP. Thirteen patients (13%) developed respiratory symptoms that warranted bronchoscopy and broncho-alveolar lavage. In all 13 patients, PJP was not identified by immunofluorescence or PCRs.
Two previous reports on the successful use of IV pentamidine to prevent PJP were in the pediatric patients. 7, 8 One study involved 54 patients 7 and another 79 patients 8 who underwent allogeneic HPC transplant. The results presented in this paper, therefore, not only represent the first report of the use of IV pentamidine as first-line prophylaxis against PJP in the non-HIV adult patients who underwent allogeneic HPC transplant but also the largest series reported from any transplant center.
Despite the heavy immunosuppression experienced by most of the studied patients, we did not observe a single case of PJP, even in the 13 patients who developed pneumonitis and underwent bronchoscopy. This is not unlike the results reported on its use as primary prophylaxis in 54 children and adolescents who underwent HPC transplant. 7 In contrast, a breakthrough rate of 1.9% was observed among the 106 transplant recipients (79 allogeneic and 18 autologous) in another study that only switched the patients to IV pentamidine if the patients were unable to tolerate oral TMP-SMZ. 8 The reason for the differences in the breakthrough rate remains speculative. It is interesting to note that the absolute protection conferred by IV pentamidine only occurred in patients who had received the IV pentamidine as the primary PJP prophylaxis. The breakthrough observed when IV pentamidine was used as second-line prophylaxis might have been related to the periods of non-protection between the time of intolerance to the TMP-SMZ and the start of IV pentamidine. During these periods, the patients might have higher Pneumocystis jirovecii loads that were not able to be controlled with the IV pentamidine but not high enough to result in clinical infections. However, breakthrough occurred because the fungal load continued to increase slowly despite the IV pentamidine and the infections manifested when the fungal load reached a certain threshold levels.
IV pentamidine was well tolerated. Infusion-related adverse reactions were not observed with any of the infusions. The only significant adverse reaction observed was an increase in the serum creatinine levels in some patients, and after 2% of the infusions. In the setting of allogeneic transplant, it is difficult to be certain of the exact role of the pentamidine in increasing the serum creatinine since all of these patients were also on other nephrotoxic drugs that included the calcineurin inhibitors and some also on IV antimicrobials such as vancomycin and amphotericin. Importantly, the increase was transient and none of the infusions were associated with the development of acute renal shutdown.
Medication compliance can be difficult in the setting of allogeneic transplant because of the high number of medications required peri-transplant. Furthermore, the irregular schedule of TMP-SMZ may lead to more forgotten doses. It is also during this period that the patients have yet to recover fully from the toxic effects of the high-dose chemoradiation, given to the patients as the conditioning regimens for the transplant, on the gastrointestinal tract. The advantages of IV pentamidine when given for PJP prophylaxis include the certainty of the pentamidine reaching the bloodstream and also the opportunity for the transplant physicians to monitor exactly the compliance for PJP prophylaxis.
In summary, our experience suggests that IV pentamidine is effective and safe in preventing PJP in adult patients undergoing allogeneic HPC transplant for hematologic malignancies. Whether or not it is better than TMP-SMZ remains to be determined in a randomized study.
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